Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

NEW YORK – DCx Biotherapeutics on Thursday said it acquired rights to certain technology platforms and small molecule therapeutic programs from Repare Therapeutics to accelerate the discovery and ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

When patients with solid tumors had the same liquid- and tissue-based test findings, patients had better outcomes on molecular tumor board-guided therapy.